Prevalence of Human Leukocyte Antigen HLA-B*57:01 Among People Living with HIV in Jazan Province, Southwestern Saudi Arabia: A Single-Centre Retrospective Cross-Sectional Study
Pathogens · 2026-11-06 · 15 (11) · 1166
DOI: 10.3390/pathogens15111166 ↗Abstract
Background: Screening for the HLA-B*57:01 allele prior to abacavir (ABC) initiation has substantially reduced the incidence of ABC-mediated hypersensitivity reactions in people living with HIV (PLWH). The frequency of HLA-B*57:01 varies markedly between populations, and regional data from southwestern Saudi Arabia have not been reported. Methods: A retrospective cross-sectional study was conducted using the medical records of PLWH attending the infectious disease clinics at King Fahad Central Hospital, Jazan, Saudi Arabia, between March 2018 and July 2021, who had undergone HLA-B*57:01 screening requested by their treating physicians as part of routine clinical care prior to a possible switch to an abacavir-containing regimen. Of 133 patients screened, 132 were analysed; as the clinic serves a nationality-mixed population, the primary analysis was restricted to Saudi nationals (n = 102). HLA-B*57:01 was genotyped by real-time PCR. Results: The cohort was predominantly male (84.8%), with a median age of 35 years. Among Saudi nationals, HLA-B*57:01 was detected in 3 of 102 patients, a prevalence of 2.9% (95% CI 0.6–8.4%), corresponding to 34 patients needing to be screened to identify one carrier. In the full cohort the prevalence was 2.3% (95% CI 0.5–6.5%), with no carrier among the 30 non-Saudi patients. Conclusions: This is the first estimate of HLA-B*57:01 prevalence reported from southwestern Saudi Arabia and the first Saudi series to report the estimate separately for Saudi nationals and the resident non-Saudi population. The estimate falls within the wide between-centre range already reported nationally. Larger multicentre studies, together with a population-based survey of Saudi donors, are needed to establish the background frequency and to evaluate routine screening.
EUVIMED